Innovative medical technology is trying to solve the problem of getting people to take their medicine, but its cost and its unfamiliarity has blocked widespread use, the Washington Post reports.

Driving the news: The first digital therapy to be approved by the Food and Drug Administration, Abilify MyCite, isn't on the market because of providers' and insurers' reservations about the product.

  • Abilify is an old drug used to treat schizophrenia and other mental illnesses. The new product is the same pill but with an electronic tracking component added, which transmits a signal when it comes into contact with stomach acid.
  • Eventually, doctors can view the data collected to monitor whether a patient is taking his or her medicine — serious information for schizophrenia patients.
  • Abilify MyCite costs $1,650 a month.

The big picture: The collision of drugs and medical devices with Silicon Valley has resulted in apps to help treat numerous health care conditions, and there are studies underway for more digital pills to treat cancer and other diseases.

  • But the cost-effectiveness of these new technologies hasn't yet been proven, and until if and when it is, that's a huge barrier to uptake.
  • "I think that these technologies have a lot of potential benefits, but it's going to be a question of evidence — that they can demonstrate value to patients and payers," former FDA Commissioner Scott Gottlieb told the Post.

Go deeper: A blind spot for medical AI

Go deeper

How Trump's push to reopen schools could backfire

Illustration: Aïda Amer/Axios

The Trump administration’s full-steam-ahead push to fully reopen schools this fall is on a collision course with the U.S.' skyrocketing coronavirus caseload and its decades-long neglect of public education.

Why it matters: Getting kids back to school is of paramount importance for children and families, especially low-income ones. But the administration isn’t doing much to make this safer or more feasible.

Coronavirus squeezes the "sandwich generation"

Illustration: Eniola Odetunde/Axios

As the coronavirus poses risks and concerns for the youngest and oldest Americans, the generations in the middle are buckling under the increasing strain of having to take care of both.

Why it matters: People that make up the so-called sandwich generations are typically in their 30s, 40s and 50s, and in their prime working years. The increasing family and financial pressures on these workers means complications for employers, too.

Why Scranton matters again in 2020

Biden and Clinton visit Biden's childhood home in Scranton in 2016. Photo: Melina Mara/The Washington Post via Getty Images

The hometown of Joe Biden and "The Office" is polishing its perennial status as a guidepost for the nation's political mood.

Driving the news: Biden returns to Scranton, Pa., today with a campaign stop just outside the city limits at a metalworking plant, where he'll deliver remarks on a plan to create jobs and "help America build back better."